Stay updated with breaking news from Jamese udelson. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Results of the 56-week VALOR-HCM trial provide new insight into the effects of mavacamten in patients with highly symptomatic obstructive hypertrophic cardiomyopathy referred for septal reduction therapy.
A novel PET perfusion radiotracer, 18F-flurpiridaz, can diagnose coronary artery disease (CAD) in obese patients with a higher sensitivity and specificity compared to 99Tc-SPECT myocardial perfusion imaging (MPI), according to research presented at the 2023 Society of Nuclear Medicine and Molecular Imaging Annual Meeting. 18F-flurpiridaz PET MPI obtained images at a lower radiation dose than 99Tc-SPECT MPI and performed similarly in both obese and non-obese patients.
A novel PET perfusion radiotracer, 18F-flurpiridaz, can diagnose coronary artery disease (CAD) in obese patients with a higher sensitivity and specificity compared to 99Tc-SPECT myocardial perfusion imaging (MPI), according to research presented at the 2023 Society of Nuclear Medicine and Molecular Imaging Annual Meeting. 18F-flurpiridaz PET MPI obtained images at a lower radiation dose than 99Tc-SPECT MPI and performed similarly in both obese and non-obese patients.
A study comparing two approaches for diagnosing heart disease found that a risk analysis strategy is superior to the usual approach of immediately performing functional tests or catheterization for low- to intermediate-risk patients with new-onset chest pain.
Personalized evaluation for chest pain effective, may eliminate unnecessary testing miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
A study comparing two approaches for diagnosing heart disease found that a risk analysis strategy is superior to the usual approach of immediately performing fu
E-Mail DALLAS, Jan. 14, 2021 -- The longer the time between when heart attack symptoms start and a patient has an artery-clearing percutaneous coronary intervention (PCI), the more damage to the heart muscle, according to new research published today in Circulation: Cardiovascular Interventions, an American Heart Association journal. A heart attack happens about every 40 seconds in the U.S., and the most common heart attack is caused by a complete blockage in a coronary artery, called ST-elevation myocardial infarction (STEMI). STEMI patients are most often treated with PCI, also known as angioplasty with stent, in which a catheter with a deflated balloon is inserted into the narrowed heart artery. Subsequently, the balloon is inflated, which clears the obstruction and restores blood flow. A stent is then inserted to keep the artery open.